2025 Half-Year Results and Business Update
Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC)
• 100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025)
• Transgene to report additional immunological data at a scientific conference in Q4 2025
Ongoing Phase II part with TG4050 in operable HNSCC
• Patient screening completed, completion of randomization expected in Q4 2025
• First immunogenicity data expected in H2 2026, and efficacy data expected in Q4 2027
Preparing new Phase I trial in an additional indication
Business funded until the end of December 2026
Conference call scheduled today at 6 p.m. CET (in English). See details below
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer